|
Global Blood Resources
|
“The
Hemobag® is able to avoid those precarious 1 & 2 unit
blood
product transfusions and extend the transfusion trigger.” |
|
Bill Shely
MD, Cardiac Surgeon
|
The association of
perioperative red blood cell transfusions and decreased long-term
survival after cardiac surgery.
Intraoperative transfusion of 1 U to 2 U packed red blood cells is
associated with increased 30-day mortality, surgical-site infection,
pneumonia, and sepsis in general surgery patients.
Ultrafiltration
Superior autologous whole blood end
product
compared to cell washed RBC volume!
Ultrafiltration reduces blood transfusions following cardiac
surgery: A meta-analysis.
Simplified Clinical Process
Easy and efficient to use with proven
results and outcomes.
Improved coagulation and blood conservation in the golden hours
after cardiopulmonary bypass.
Economic Benefit
Reduction in blood component use
results in reduced costs for everyone involved.
Examples of
Hemobag® cost savings
On-line autotransfusion waste calculator
The Hemobag®
Global Blood Resources,
Global Blood Resources is a cardiovascular surgery product and technology
company focused on optimizing a patient’s coagulation and hematologic
profile by maximizing the use of Ultrafiltration technology with its Hemobag®
and TS3 tubing set products.
The Hemobag® concept and technology are a complete and
reproducible process of managing the patient’s own blood in the
cardiopulmonary bypass (CPB) circuit both during and after CPB use. After
the termination of CPB not only are the patient’s red blood cells
concentrated, but equally as important and generally not attainable in other
currently available technologies, is that the patient’s plasma components are
both saved and concentrated. These components include platelets, clotting
factors and plasma proteins essential to the stability, coagulation and
homeostasis of the surgical patient, at the right time while keeping the ECC
still primed to emergently go back on.
The results of using this concept and technology are immediate dramatic
improvements in post CPB coagulation profile and CBC tests, with solid
evidence-based medical benefits, as well as economic benefits (cost savings)
to the patient, hospital and healthcare system.
TOP
www.MyBloodFirst.com
1-800-942-9243
|
